Clinical Trial Update: A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) [Phase 3]

View source ↗

Summary

Phase 3 ENZAMET trial comparing enzalutamide plus androgen deprivation therapy versus placebo plus ADT in metastatic hormone-sensitive prostate cancer has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Metastatic Hormone Sensitive Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2020-01-21